StockNews.com began coverage on shares of Arcadia Biosciences (NASDAQ:RKDA – Free Report) in a research note released on Tuesday morning. The brokerage issued a sell rating on the basic materials company’s stock.
Separately, HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Arcadia Biosciences in a research report on Wednesday, August 21st.
Read Our Latest Analysis on Arcadia Biosciences
Arcadia Biosciences Price Performance
Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The basic materials company reported $0.78 earnings per share for the quarter, missing the consensus estimate of $1.27 by ($0.49). Arcadia Biosciences had a negative return on equity of 57.51% and a negative net margin of 127.29%. The business had revenue of $1.31 million during the quarter, compared to analyst estimates of $0.95 million. During the same period in the prior year, the business posted ($2.64) EPS. On average, equities research analysts anticipate that Arcadia Biosciences will post -1.7 earnings per share for the current fiscal year.
About Arcadia Biosciences
Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.
Further Reading
- Five stocks we like better than Arcadia Biosciences
- How to Use the MarketBeat Dividend Calculator
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- Most Volatile Stocks, What Investors Need to Know
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- How to Start Investing in Real Estate
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.